ABVC BioPharma, Inc.
Past financial statements no longer reliable (8-K Item 4.02)
The company stated in a Form 8-K (Item 4.02) filed on 03 Mar 2026 that previously issued financial statements should no longer be relied upon. This usually leads to a restatement of past results.
More details →Change of auditor (8-K Item 4.01)
The company reported a change of its independent auditor in a Form 8-K (Item 4.01) filed on 02 Jul 2026. Auditor changes are often routine (rotation, cost, mergers), but can follow disagreements over accounting.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 15 May 2026, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →ABVC BioPharma, Inc. — Overview & Financial Snapshot
ABVC BioPharma, Inc. (NasdaqCM: ABVC) is a Healthcare company, ranked #3,631 of 6,775 companies globally and #1,589 of 4,000 in United States on PositoAI, with a Positivity Score of 20,415. Its market capitalisation is ₹263.89 Cr ($27.96M), P/E ratio is -3.5 and P/B ratio is 2.72. It has no active red flags (PosiRed) and 3 yellow flags (PosiYellow, 10/10 points).
For financial statements, ratio trends and score history, Go Deep →